Treatment for Dangerous Allergies

Arnie Phifer | Oct. 7, 2013 | Notre Dame College of Science

Peanut allergy

New research published in the journal Nature Chemical Biology shows that a group of scientists, led by faculty at the University of Notre Dame, has made concrete progress toward the development of the first-ever inhibitory therapeutic for type-I hypersensitive allergic reactions.

“Our allergy inhibition project is innovative and significant because we brought a novel molecular design approach to selectively inhibit ‘mast cell degranulation’–the key event in triggering a food allergic response–which has the potential to improve the quality of life for affected patients,” explains Basar Bilgicer, assistant professor of chemical and biomolecular engineering at Notre Dame and an investigator in the university’s Advanced Diagnostics & Therapeutics initiative.

Read more at Notre Dame's Advanced Diagnistics & Therapeutics initiative

 by Daily Domer Staff

Posted In: Features